News

Business Wire5mon
Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201
ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness ...
Yahoo Finance2y
Blue Lake Biotechnology to Be Featured at the Biotechnology Innovation Organization (BIO) International Convention
ATHENS, Ga. and LOS GATOS, Calif., May 31, 2023 /PRNewswire/ -- Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company harnessing the full breadth of the immune system to ...
Morningstar2mon
Blue Lake Biotechnology to Present Safety and Immunogenicity Data for its RSV Intranasal Vaccine Candidate at the 13th International RSV Symposium
Morningstar brands and products Company Portfolio ...
Morningstar7mon
Blue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect ...